Skip directly to site content
Are You Still There?
Due to inactivity, you will be signed out in two minutes unless you click 'Continue'.

Are you still there?

Due to inactivity, you will be signed out in two minutes unless
you click 'Continue'.

Panel:   4300 (Custom)
AR Bank # 0289 Acinetobacter baumannii
Study ID: ACI-17

Biosample Accession #: SAMN04901679

   
Source: Bronchial washings
MLST: ST2(Pasteur), ST348(Oxford)


Panel:  Acinetobacter baumannii (ACI)


MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Amikacin 32I
Ampicillin/sulbactam 132R
Cefepime >32R
Cefiderocol 0.25S
Cefotaxime >64R
Ceftazidime 128R
Ceftriaxone >32R
Ciprofloxacin >8R
Colistin 44R
Doripenem >8R
Gentamicin >16R
Imipenem >64R
Imipenem/relebactam 3>16R
Imipenem+chelators 2>32---
Levofloxacin >8R
Meropenem >8R
Minocycline 16R
Piperacillin/tazobactam 1>128R
Tetracycline >32R
Tigecycline 32---
Tobramycin >16R
Trimethoprim/sulfamethoxazole 1>8R
MICs obtained by broth microdilution. Modal MIC is reported
S – I –R Interpretation (INT) derived from CLSI 2024 M100 S34
1 Reflects MIC of first component
2 Screen for metallo-beta-lactamase production [Rasheed et al. Emerging Infectious Diseases. 2013. 19(6):870-878]
3 Based on FDA break points
4 Clinical and PK/PD data demonstrate colistin has limited clinical efficacy, even if an intermediate result is obtained. Alternative agents are strongly preferred. Colistin should be used in combination with one or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended.
Device manufacturers and users of FDA cleared devices shall consult the FDA’s Antibacterial Susceptibility Test Interpretive Criteria       website for breakpoints recognized or recommended by FDA, and for information regarding FDA exceptions or additions to the applicable, recognized consensus standard.
Molecular Mechanisms of Resistance
CategoryGene
Aminoglycoside aac(3)-Ia, aacA16, aph(6)-Id, strA
Beta-lactam ADC-30, OXA-66, OXA-72
Efflux pumps/Other ADEC
Fosfomycin ABAF
Sulfonamides sul2
Tetracyclines tet(B)
 
Disclaimer:
No disclaimer.
Propagation
MEDIUM
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

GROWTH CONDITIONS
Temperature: 35°C
Atmosphere: Aerobic

PROPAGATION PROCEDURE

Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)

Open vial aseptically to avoid contamination

Using a sterile loop, remove a small amount of frozen isolate from the top of the vial

Aseptically transfer the loop to BAP

Use streak plate method to isolate single colonies

Incubate inverted plate at 35°C ± 2 °C for 20-24 hrs.
Storage Temperature & Biosafety
STORAGE TEMPERATURE: -70°C

BIOSAFETY LEVEL: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.



Disclaimer:

Isolate History
Date Action Performed
05/09/23Gene was added to 'aacA16'
05/09/23Gene was removed from 'from '---' to ' aadA16''
05/02/23MLST was updated: from '---' to 'ST348(Oxford)'
05/02/23MLST was updated: from '---' to 'ST2(Pasteur)'
05/02/23Gene was added to 'ADEC'
05/02/23Gene was added to 'tet(B)'
05/02/23Gene was added to 'ABAF'
05/02/23Gene was added to 'ADC-30'
05/02/23Gene was added to 'aph(6)-Id'
05/02/23Gene was added to 'aadA16'
05/02/23Category was added: 'Efflux pumps/Other'
05/02/23Category was added: 'Tetracyclines'
05/02/23Category was added: 'Fosfomycin'
05/02/23Gene was removed from 'from '---' to ' ADC-25''
05/02/23Gene was removed from 'from '---' to ' strB''
08/11/22INT was updated with a new value for Cefiderocol: from '---' to 'S'
08/11/22MIC was updated with a new value for Cefiderocol: from '---' to '0.25'
08/11/22Drug was added: Cefiderocol
Top of Page
TOP